AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic...

Press/Media: Press / Media

PeriodNov 20 2015

Media coverage

1

Media coverage

  • TitleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic...
    Media name/outletPharmacy Choice
    CountryUnited States
    Date11/20/15
    PersonsFred Poordad